Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Work In Process (2019 - 2025)

Ptc Therapeutics (PTCT) has 7 years of Work In Process data on record, last reported at $55.7 million in Q4 2025.

  • For Q4 2025, Work In Process rose 355.84% year-over-year to $55.7 million; the TTM value through Dec 2025 reached $55.7 million, up 355.84%, while the annual FY2025 figure was $55.7 million, 355.84% up from the prior year.
  • Work In Process reached $55.7 million in Q4 2025 per PTCT's latest filing, up from $41.8 million in the prior quarter.
  • Across five years, Work In Process topped out at $55.7 million in Q4 2025 and bottomed at $7.0 million in Q2 2022.
  • Average Work In Process over 5 years is $18.4 million, with a median of $16.0 million recorded in 2022.
  • The widest YoY moves for Work In Process: up 355.84% in 2025, down 41.09% in 2025.
  • A 5-year view of Work In Process shows it stood at $7.7 million in 2021, then soared by 82.28% to $14.1 million in 2022, then grew by 27.83% to $18.0 million in 2023, then plummeted by 32.1% to $12.2 million in 2024, then skyrocketed by 355.84% to $55.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $55.7 million in Q4 2025, $41.8 million in Q3 2025, and $24.4 million in Q2 2025.